1. Home
  2. ATHA vs OXBR Comparison

ATHA vs OXBR Comparison

Compare ATHA & OXBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • OXBR
  • Stock Information
  • Founded
  • ATHA 2011
  • OXBR 2013
  • Country
  • ATHA United States
  • OXBR Cayman Islands
  • Employees
  • ATHA N/A
  • OXBR N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • OXBR Property-Casualty Insurers
  • Sector
  • ATHA Health Care
  • OXBR Finance
  • Exchange
  • ATHA Nasdaq
  • OXBR Nasdaq
  • Market Cap
  • ATHA 14.8M
  • OXBR 15.1M
  • IPO Year
  • ATHA 2020
  • OXBR 2014
  • Fundamental
  • Price
  • ATHA $0.36
  • OXBR $2.45
  • Analyst Decision
  • ATHA Hold
  • OXBR Strong Buy
  • Analyst Count
  • ATHA 3
  • OXBR 1
  • Target Price
  • ATHA $0.50
  • OXBR $5.00
  • AVG Volume (30 Days)
  • ATHA 149.8K
  • OXBR 57.5K
  • Earning Date
  • ATHA 11-06-2025
  • OXBR 11-12-2025
  • Dividend Yield
  • ATHA N/A
  • OXBR N/A
  • EPS Growth
  • ATHA N/A
  • OXBR N/A
  • EPS
  • ATHA N/A
  • OXBR N/A
  • Revenue
  • ATHA N/A
  • OXBR $1,983,000.00
  • Revenue This Year
  • ATHA N/A
  • OXBR $497.99
  • Revenue Next Year
  • ATHA N/A
  • OXBR $42.14
  • P/E Ratio
  • ATHA N/A
  • OXBR N/A
  • Revenue Growth
  • ATHA N/A
  • OXBR N/A
  • 52 Week Low
  • ATHA $0.22
  • OXBR $1.27
  • 52 Week High
  • ATHA $0.83
  • OXBR $5.81
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 36.59
  • OXBR 70.75
  • Support Level
  • ATHA $0.35
  • OXBR $1.93
  • Resistance Level
  • ATHA $0.40
  • OXBR $2.35
  • Average True Range (ATR)
  • ATHA 0.02
  • OXBR 0.19
  • MACD
  • ATHA -0.00
  • OXBR 0.05
  • Stochastic Oscillator
  • ATHA 11.86
  • OXBR 95.59

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

About OXBR Oxbridge Re Holdings Limited

Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.

Share on Social Networks: